Warning

APREMILAST Treatment 2026 (A Phosphodiesterase-4 inhibitor) 

INFORMATION FOR GENERAL PRACTITIONERS 

The aim of treatment is to suppress disease activity and preserve joint function in the Psoriatic arthritis. 

Dosage

  • Prescribed by Hospital (due to cost saving) 
  • Starter Pack-10mg day 1,
  • 10mg twice daily day 2 
  • 10mg morning , 20mg evening day 3, 20mg twice daily day 4, 
  • 20mg morning 30mg evening day 5, then 30mg twice daily ongoing- 12 hours apart. 
  • Taking with food, especially carbohydrate foods can ameliorate any early nausea/diarrhoea and avoid caffeine in first couple of weeks 

Reduce dose to 30mg once daily if eGFR <30 

Stop during serious Infection 

Monitoring Procedure

None Required

Flares

  • Disease modifying drugs will not prevent all flares.  
  • These can be managed with IM Depo Steroid as outlined above.  
  • If flares become more frequent, or the disease fails to settle between flares an alternative can be discussed with the Rheumatologist. 

Contraindications

Pregnancy, Breastfeeding 

Cautions/Side effects

  • Rare association with suicidal thoughts  
  • Stop if unexplained/significant weight loss 
  • GI symptoms, headaches common and usually short lasting 

Interactions

See BNF – Carbamazepine, Phenytoin, St John’s Wort 

Duration of Treatment and Time to Response

  • Treatment is continued indefinitely providing it remains effective and there are no significant side effects.  
  • Apremilast takes up to 26 weeks to become effective but may take 6 months.  
  • During this period there are likely to be continued symptoms or signs of disease activity.  
  • It is reasonable to use IM Depo steroids (Kenalog 40 mg or Depo Medrone 80 mg) up to monthly, depending on the requirements of the individual patient.  
  • The dose required is small (eg monthly Kenalog 40 mg = 1.6 mg Prednisolone daily). 

Hospital Contact

*Secretary 01387 241776  

*Helpline 01387 241095 Rheumatology Nurse Specialists 

  Doctors-via Switchboard 

Editorial Information

Last reviewed: 12/03/2026

Next review date: 12/03/2028

Author(s): Dr Lucy Moran.